UNLABELLED: Mutations in the p53 gene can play a role in the transformation of normal to malignant cells. Because these mutations are more frequently reported later in the course of transformation, their presence could reflect a greater malignant potential of the tumor and, thus, an increased probability of metastasis and recurrence after local therapy. In a pilot study using single-stranded conformation polymorphism analysis (SSCP), 200 node-negative breast tumors were examined for mutations in the region encompassing exons 5 through 9 of the p53 gene. Exons 5 through 9 were tested because they contain 80-90% of known p53 gene mutations. The tumors ranged in size from 1 to 3 cm. 28 tumors were found to have an abnormal band pattern on both initial and repeat analysis. 4 of these tumors were sequenced; 3 contained a p53 mutation and the 4th had a rare neutral polymorphism. Disease-free survival (DFS) at 5 years for women with tumors having an abnormal SSCP analysis was 57% (+/- 10%), compared to a 79% (+/- 3%) DFS for the group with a normal pattern. By the log rank test, this difference was highly significant, p < or = 0.01. The relative risk of recurrence for the group with an abnormal SSCP pattern was 2.2. In a multivariate analysis including ER, PgR, ploidy, S-phase, age, and tumor size, an abnormal p53 by SSCP analysis and patient age were the only factors that independently predicted DFS at 5 years. CONCLUSION: Women with node-negative breast cancer who have tumors with alterations in the p53 gene, as indicated by SSCP analysis, have a significantly poorer prognosis and a higher rate of relapse at 5 years. The prognostic significance is maintained in a multivariate analysis including many established prognostic factors.
UNLABELLED: Mutations in the p53 gene can play a role in the transformation of normal to malignant cells. Because these mutations are more frequently reported later in the course of transformation, their presence could reflect a greater malignant potential of the tumor and, thus, an increased probability of metastasis and recurrence after local therapy. In a pilot study using single-stranded conformation polymorphism analysis (SSCP), 200 node-negative breast tumors were examined for mutations in the region encompassing exons 5 through 9 of the p53 gene. Exons 5 through 9 were tested because they contain 80-90% of known p53 gene mutations. The tumors ranged in size from 1 to 3 cm. 28 tumors were found to have an abnormal band pattern on both initial and repeat analysis. 4 of these tumors were sequenced; 3 contained a p53 mutation and the 4th had a rare neutral polymorphism. Disease-free survival (DFS) at 5 years for women with tumors having an abnormal SSCP analysis was 57% (+/- 10%), compared to a 79% (+/- 3%) DFS for the group with a normal pattern. By the log rank test, this difference was highly significant, p < or = 0.01. The relative risk of recurrence for the group with an abnormal SSCP pattern was 2.2. In a multivariate analysis including ER, PgR, ploidy, S-phase, age, and tumor size, an abnormal p53 by SSCP analysis and patient age were the only factors that independently predicted DFS at 5 years. CONCLUSION:Women with node-negative breast cancer who have tumors with alterations in the p53 gene, as indicated by SSCP analysis, have a significantly poorer prognosis and a higher rate of relapse at 5 years. The prognostic significance is maintained in a multivariate analysis including many established prognostic factors.
Authors: J H Kim; T Takahashi; I Chiba; J G Park; M J Birrer; J K Roh; H De Lee; J P Kim; J D Minna; A F Gazdar Journal: J Natl Cancer Inst Date: 1991-07-03 Impact factor: 13.506
Authors: A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall Journal: J Natl Cancer Inst Date: 1992-06-03 Impact factor: 13.506
Authors: Stefan S Bozhanov; Svetla G Angelova; Maria E Krasteva; Tsanko L Markov; Svetlana L Christova; Ivan G Gavrilov; Elena I Georgieva Journal: J Cancer Res Clin Oncol Date: 2010-02-23 Impact factor: 4.553
Authors: T Megha; F Ferrari; A Benvenuto; C Bellan; A V Lalinga; S Lazzi; S Bartolommei; G Cevenini; L Leoncini; P Tosi Journal: J Clin Pathol Date: 2002-06 Impact factor: 3.411
Authors: M D Thomas; G G McIntosh; J J Anderson; D M McKenna; A H Parr; R Johnstone; T W Lennard; C H Horne; B Angus Journal: J Clin Pathol Date: 1997-02 Impact factor: 3.411
Authors: J S Kovach; A Hartmann; H Blaszyk; J Cunningham; D Schaid; S S Sommer Journal: Proc Natl Acad Sci U S A Date: 1996-02-06 Impact factor: 11.205